Genenta ends Ospedale San Raffaele license deal

Genenta Science S.p.A. has approved the termination of its amended and restated license agreement with Ospedale San Raffaele, which covered certain technology and intellectual property rights licensed to the company.

Rhea-AI Filing Summary

Genenta Science S.p.A. has approved the termination of its amended and restated license agreement with Ospedale San Raffaele, which covered certain technology and intellectual property rights licensed to the company. The termination will end the licenses and option rights granted under the agreement, except for surviving and wind-down provisions and any accrued obligations.

The company does not expect any material termination fee or penalty beyond obligations already accrued. Management reached this decision after reviewing strategic priorities and plans to redirect resources to ongoing business and strategic initiatives. Genenta will continue to support and monitor its active glioblastoma multiforme clinical trial, where two patients are currently under observation.

Insights

Biotech strategy analyst

Genenta ends a legacy IP license, citing strategy, while keeping its GBM trial active.

Genenta Science is terminating an amended and restated license with Ospedale San Raffaele covering certain technology and intellectual property. The agreement’s licenses and option rights will cease, aside from surviving and wind-down terms and accrued obligations.

The company explicitly does not expect a material termination fee or penalty beyond accrued obligations, which limits near-term financial impact. Management links the move to a strategic review and plans to reallocate resources toward existing business and initiatives.

Importantly for pipeline visibility, the glioblastoma multiforme clinical trial remains active, with two patients under observation. Future disclosures in company filings will be key to understanding how this license termination affects longer-term development plans and any reliance on OSR-related technology.

Key Figures

GBM trial patients: 2 patients

1 metrics

GBM trial patients 2 patients Currently under observation in glioblastoma multiforme clinical trial

Key Terms

amended and restated license agreement, intellectual property rights, glioblastoma multiforme, forward-looking statements

4 terms

amended and restated license agreement regulatory

"the Company’s amended and restated license agreement with Ospedale San Raffaele"

intellectual property rights financial

"relating to certain technology and intellectual property rights licensed by OSR"

Legal protections that give a company exclusive control over creations like inventions, brand names, designs, formulas, software and creative works, similar to owning the lock and key to a recipe or product design. For investors, these rights matter because they can create durable revenue streams, reduce competition and justify higher company value, while weak or contested rights increase the risk of lost sales and costly legal disputes.

glioblastoma multiforme medical

"the ongoing glioblastoma multiforme (“GBM”) clinical trial"

An aggressive form of brain cancer that grows quickly and spreads into nearby brain tissue, often causing severe symptoms and limited treatment options. For investors, glioblastoma matters because it defines a high unmet medical need and a potentially large market for new drugs, devices, or diagnostics; success or failure in clinical trials and regulatory reviews for glioblastoma treatments can dramatically affect the valuation and risk profile of healthcare companies, like a make-or-break product for a small biotech.

forward-looking statements regulatory

"This report contains forward-looking statements within the meaning of applicable securities laws"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What agreement did Genenta Science (GNTA) terminate with Ospedale San Raffaele?

Genenta decided to terminate its amended and restated license agreement with Ospedale San Raffaele, which covered certain technology and intellectual property rights. The termination ends associated licenses and option rights, subject to surviving provisions, wind-down obligations, and any obligations already accrued under the agreement.

Will Genenta Science (GNTA) pay a termination fee for ending the OSR license?

Genenta does not expect to incur any material termination fee or penalty from ending the Ospedale San Raffaele license. The company only anticipates honoring accrued obligations already existing under the agreement, which helps limit the immediate financial impact of this strategic decision.

Why is Genenta Science (GNTA) ending its license with Ospedale San Raffaele?

Genenta made the termination decision after reviewing its strategic priorities and resource allocation. Management intends to reallocate resources toward ongoing business and strategic initiatives, indicating a refocusing of effort rather than a response to an explicit financial or legal penalty tied to the agreement.

How does the OSR license termination affect Genenta’s GBM clinical trial?

Genenta states it will continue to support and monitor its glioblastoma multiforme clinical trial, which remains active. Two patients are currently under observation in this study, suggesting that the OSR license termination does not immediately halt or suspend this specific clinical program.

Does Genenta Science (GNTA) provide forward-looking statements about the termination impact?

Yes. The company includes forward-looking statements about the expected impacts of the termination and future strategic plans. These are based on current expectations and subject to risks and uncertainties, and Genenta disclaims any obligation to update them except as required by applicable law.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 05:08 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-41115

GENENTA SCIENCE S.P.A.

(Translation of registrant’s name into English)

Via dell’Annunciata 31

20121 Milan, Italy

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

This report on Form 6-K, including Exhibit 10.1, is incorporated by reference into the registrant’s registration statement on Form F-3 (File No. 333-271901).

Other Events

Ospedale San Raffaele License Termination

On May 18, 2026, the Board of Directors of Genenta Science S.p.A. (the “Company”) approved the delivery of a notice of termination of the Company’s amended and restated license agreement with Ospedale San Raffaele S.r.l. (“OSR”), relating to certain technology and intellectual property rights licensed by OSR to the Company.

Subject to the terms of the agreement, the termination will result in the termination of the licenses and option rights granted to the Company under the agreement, subject to any surviving provisions, wind-down obligations, and accrued obligations thereunder. The Company does not expect to incur any material termination fee or penalty in connection with the termination, other than any accrued obligations under the agreement.

The Company made this determination following a review of its strategic priorities and resource allocation. The Company expects to reallocate resources toward its ongoing business and strategic initiatives.

The Company will continue to support and monitor the ongoing glioblastoma multiforme (“GBM”) clinical trial, which remains active with two patients currently under observation.

Forward-Looking Statements

This report contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the expected impacts of the termination and future strategic plans of the Company. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. The Company undertakes no obligation to update these forward-looking statements except as required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GENENTA SCIENCE S.P.A.
	By:	/s/ Pierluigi Paracchi
	Name:	Pierluigi Paracchi
	Title:	Chief Executive Officer

Dated: May 19, 2026

Exhibits.

Exhibit No.		Description
10.1		Termination Notice Dated May 18, 2026

Filing Exhibits & Attachments

2 documents

Agreements & Contracts

• EX-10.1 EX-10.1 10.5 KB

Other Documents

• EX-10 GRAPHIC 14.9 KB